Exciting research in the field of lung cancer

• 1.Dactini is expected to be a new treatment option for patients with advanced EGFR mutation positive non-small cell lung cancer (NSCLC)

In 2017, presented at the annual meeting of the American society of clinical oncology ARCHER 1050 results show that for mike, the treatment compared with a generation of EGFR inhibitors in progression-free surial (PFS) and alleviate the duration has more advantages, is expected to become the late EGFR mutation positive patients with non-small cell lung cancer (NSCLC) new treatment options.

The study included 452 cases of IIIB or stage IV EGFR positive NSCLC patients, and subjects were randomly assigned to the dactini group (45 mg PO QD) or the gefitinib group (250 mg PO QD).

It was found that the total remission rate of similarity between the two groups (74.9 vs 71.6, P < 0.3883), but for mike, the treatment vs patients with median PFS was 14.7 months versus 9.2 months, respectively, to alleviate duration 14.8 vs. 8.3 months, respectively, indicating that for mike, treatment of advanced EGFR mutation positive non-small cell lung cancer (NSCLC) the treatment curative effect far beyond.

It is worth noting that even for mike's dose by 45 mg down to 30 mg or 15 mg, alleviate the treatment time is longer than the treatment group, the treatment close to set more than 2 times (11.3 vs. 5.2 months).

In addition, no new safety signals have been observed.

Tak for, is the second generation of EGFR targeted drug targets and the method for same as EGFR, HER2, HER4, but unfortunately, the study did not include patients with brain metastases, so for alternative into the brain ability needs further study.

• 2.The efficacy of ellotinib in the treatment of ALK fusion mutation positive for advanced non-small cell lung cancer was more effective than in the first line of trizidine

In the field of non-small-cell lung cancer, a study comparing the head-to-head studies of elatinib and keazinib is refreshing.

Research reports, positive for mutations in the ALK fusion advanced non-small cell lung cancer (NSCLC) patients treated first USES the second generation ALK, after treatment for targeted drug elle, tumor progression-free surial (PFS) can reach 25.7 months, this is unprecedented in the field of NSCLC treatment, compared with the generation of ALK, for targeted drug g azole, tumor progression-free surial was fully extended for 15 months.

As a result, The study has been chronicled in The New England Journal of Medicine.

ALEX is a randomized, open label of the third phase of clinical trial, in the process of the experiment, the researchers recruited to the end of the 303 cases of ALK positive (IIIB - IV) in patients with non-small cell lung cancer, these patients always have not received systemic therapy for advanced disease.

The patients were randomly divided into the ellotinib group (n = 152, oral 600 mg, twice daily) and the group of kazolinib (n = 151, with oral 250mg, twice daily).

The results showed that the median unprogressiveness of the group was 10.4 months, and the objective remission rate (ORR) was 76%.

However, there was no progress in the ellotinib group at 25.7 months, and the objective remission rate was about 83%.

Elatinib significantly lengthened the patient's progress by about 15 months, reducing the risk of tumor progression by 53 percent.

It is worth mentioning that brain metastasis (CNS) of that part of the group of patients, thiazole, for treatment of intracranial remission rate was 50%, the 12 months to 41.4% intracranial progress, and elle for treatment of intracranial remission rate was 81%, 12 months intracranial progress rate is only 9.4%.

It also suggests that ellotini has an advantage in preventing brain metastasis.

In terms of the safety of drug use, ellotini was more secure (a 41 percent versus 50 percent incidence of serious side effects) compared to kazolinib.

The most common side effects of ellotini are fatigue, constipation, muscle soreness and swelling, while keazinib is a gastrointestinal problem and a liver enzyme abnormality.

In non-small cell lung cancer, according to some genetic variation with respective targeted drugs, though their effect is also very good, but the existing clinical data showed that tumor progression time around 1 year commonly, never break through 2 years.

In this study, for positive ALK advanced non-small cell lung cancer patients, elle, tumor progression-free surial for's control in 25.7 months, clinical data of the brilliant once again broke the pattern of the treatment of non-small cell lung cancer, refresh the lung cancer treatment.

• 3.The effect of MET inhibitor on survival of phenotype 14 mutant NSCLC patients

One of the more profound studies in the field of lung cancer in this conference is that the MET inhibitor has a therapeutic response to MET exon 14 (METdel14) mutant NSCLC.

In this summary, the researchers reported a retrospective analysis of a multicenter study that included 148 patients with METdel14 mutation NSCLC, most of which are adenocarcinoma and sarcoma.

70% of the patients were diagnosed with i-iii NSCLC and 30% stage IV disease.

Among the 34 patients who had not received the MET inhibitor for the treatment of metastatic NSCLC, the median OS was 8.1 months, while the patients with MET amplification had a worse trend (5.2 vs. 10.5 months, P = 0.06).

In patients with metastatic NSCLC with at least one MET inhibitor, the median OS was 24.6 months and the MET inhibitor significantly improved survival (HR = 0.11).

The median PFS was 7.36 months.

The study found that patients treated with MET inhibitors had an OS benefit.

Patients who did not receive the MET inhibitor treatment had a worse prognosis, especially with simultaneous enlargement of the patient.

Although the MET is not advanced NSCLC routine detection of molecular markers, but this kind of research may further promote the clinical detection to carry out a wider range of genome, because list of clinically relevant markers in continuous expansion.

This type of study will urge oncologists to continue to explore the MET inhibitor therapy, ideally in clinical trials of patients with advanced NSCLC with the presence of the MET exon 14 mutation.

prev:What is the serum trap on the market(2017-07-02)

next:Exciting research in the field of liver cancer(2017-07-03)